Literature DB >> 21826740

Monitoring humans for somatic mutation in the endogenous PIG-a gene using red blood cells.

Vasily N Dobrovolsky1, Rosalie K Elespuru, C Anita H Bigger, Timothy W Robison, Robert H Heflich.   

Abstract

The endogenous X-linked PIG-A gene is involved in the synthesis of glycosyl phosphatidyl inositol (GPI) anchors that tether specific protein markers to the exterior of mammalian cell cytoplasmic membranes. Earlier studies in rodent models indicate that Pig-a mutant red blood cells (RBCs) can be induced in animals treated with genotoxic agents, and that flow cytometry can be used to identify rare RBCs deficient in the GPI-anchored protein, CD59, as a marker of Pig-a gene mutation. We investigated if a similar approach could be used for detecting gene mutation in humans. We first determined the frequency of spontaneous CD59-deficient RBCs (presumed PIG-A mutants) in 97 self-identified healthy volunteers. For most subjects, the frequency of CD59-deficient RBCs was low (average of 5.1 ± 4.9 × 10(-6) ; median of 3.8 × 10(-6) and mutant frequency less than 8 × 10(-6) for 75% of subjects), with a statistically significant difference in median mutant frequencies between males and females. PIG-A RBC mutant frequency displayed poor correlation with the age and no correlation with the smoking status of the subjects. Also, two individuals had markedly increased CD59-deficient RBC frequencies of ∼300 × 10(-6) and ∼100 × 10(-6) . We then monitored PIG-A mutation in 10 newly diagnosed cancer patients undergoing chemotherapy with known genotoxic drugs. The frequency of CD59-deficient RBCs in the blood of the patients was measured before the start of chemotherapy and three times over a period of ∼6 months while on/after chemotherapy. Responses were generally weak, most observations being less than the median mutant frequency for both males and females; the greatest response was an approximate three-fold increase in the frequency of CD59-deficient RBCs in one patient treated with a combination of cisplatin and etoposide. These results suggest that the RBC PIG-A assay can be adopted to measuring somatic cell mutation in humans. Further research is necessary to determine the assay's sensitivity in detecting mutations induced by genotoxic agents acting via different mechanisms.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826740     DOI: 10.1002/em.20667

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  11 in total

1.  Both PIGA and PIGL mutations cause GPI-a deficient isolates in the Tk6 cell line.

Authors:  Janice A Nicklas; Elizabeth W Carter; Richard J Albertini
Journal:  Environ Mol Mutagen       Date:  2015-05-13       Impact factor: 3.216

2.  In vivo pig-a and micronucleus study of the prototypical aneugen vinblastine sulfate.

Authors:  Svetlana L Avlasevich; Carson Labash; Dorothea K Torous; Jeffrey C Bemis; James T MacGregor; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-08-19       Impact factor: 3.216

3.  Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Dorothea K Torous; Jeffrey C Bemis; Souk Phonethepswath; Carson Labash; Kristine Carlson; Jared Mereness; John Cottom; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

4.  Human erythrocyte PIG-A assay: an easily monitored index of gene mutation requiring low volume blood samples.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Jeffrey C Bemis; Yuhchyau Chen; James T MacGregor
Journal:  Environ Mol Mutagen       Date:  2014-11-20       Impact factor: 3.216

5.  Sensitivity of the Pig-a assay for detecting gene mutation in rats exposed acutely to strong clastogens.

Authors:  Javed A Bhalli; Joseph G Shaddock; Mason G Pearce; Vasily N Dobrovolsky
Journal:  Mutagenesis       Date:  2013-05-15       Impact factor: 3.000

6.  Single cell gel electrophoresis (SCGE) and Pig-a mutation assay in vivo-tools for genotoxicity testing from a regulatory perspective: a study of benzo[a]pyrene in Ogg1(-/-) mice.

Authors:  Anne Graupner; Christine Instanes; Stephen D Dertinger; Jill Mari Andersen; Birgitte Lindeman; Tonje Danielsen Rongved; Gunnar Brunborg; Ann-Karin Olsen
Journal:  Mutat Res Genet Toxicol Environ Mutagen       Date:  2014-08-07       Impact factor: 2.873

7.  Absence of in vivo mutagenicity of multi-walled carbon nanotubes in single intratracheal instillation study using F344 gpt delta rats.

Authors:  Katsuyoshi Horibata; Akiko Ukai; Akio Ogata; Dai Nakae; Hiroshi Ando; Yoshikazu Kubo; Akemichi Nagasawa; Katsuhiro Yuzawa; Masamitsu Honma
Journal:  Genes Environ       Date:  2017-01-06

8.  Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma.

Authors:  Hasan N Haboubi; Rachel L Lawrence; Benjamin Rees; Lisa Williams; James M Manson; Neam Al-Mossawi; Owen Bodger; Paul Griffiths; Catherine Thornton; Gareth J Jenkins
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

9.  The frequency of granulocytes with spontaneous somatic mutations: a wide distribution in a normal human population.

Authors:  Tommaso Rondelli; Margherita Berardi; Benedetta Peruzzi; Luca Boni; Roberto Caporale; Piero Dolara; Rosario Notaro; Lucio Luzzatto
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Development of an in vitro PIG-A gene mutation assay in human cells.

Authors:  Benjamin J Rees; Matthew Tate; Anthony M Lynch; Catherine A Thornton; Gareth J Jenkins; Richard M Walmsley; George E Johnson
Journal:  Mutagenesis       Date:  2017-03-01       Impact factor: 2.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.